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Abstract Cells inﬁltrating into normal brain from
malignant brain tumors are protected by the blood brain
barrier (BBB) which prevents the delivery and limits the
effects of anti-tumor agents. We have evaluated the ability
of photochemical internalization (PCI) to limit the effects
of an agent known to broadly open the BBB to a target
region of the brain. The PCI-based relocation and activa-
tion of macromolecules into the cell cytosol has the
advantage of minimal side effects since the effect is
localized to the area exposed to light, allowing the access
of chemotherapeutic agents only to these regions. Non
tumor bearing inbred Fisher rats were treated with pho-
tosesitizer, and a nontoxic intraperitoneal dose of Clos-
tridium perfringens epsilon prototoxin (ETXp) followed by
light exposure. Post-contrast T1 MRI scans were used to
monitor the degree BBB disruption. F98 tumor cells were
implanted into the brains of other animals that were sub-
sequently treated 24 h later with ETXp-PCI BBB opening
followed by the i.p. administration of bleomycin (BLM).
PCI delivery of ETXp at low ﬂuence levels demonstrated
signiﬁcant MRI enhancement. No effect on the BBB was
observed if photosesitizer and light was given in the
absence ETXp. The survival of animals implanted with F98
tumor cells was signiﬁcantly extended following ETXp-
PCI BBB opening and BLM therapy compared to controls.
PCI delivered ETXp was effective in opening the BBB in a
limited region of the brain. ETXp-PCI mediated BBB
opening clearly increased the efﬁcacy of BLM therapy.
Keywords Blood brain barrier   Brain tumor  
Bleomycin   Photochemical internalization   PDT  
Clostridium perfringens prototoxin   Targeted opening
Introduction
Although gross total resection of gliomas, as evaluated on
post-operative MRI, is often possible with current available
techniques, patients continue to relapse due to the inﬁl-
trative nature of these tumors despite post-operative radi-
ation and chemotherapy. Both individual cells and micro-
colonies of tumor cells have been shown to inﬁltrate in or
beyond a region of brain-adjacent-to-tumor (BAT)—a zone
that may extend several centimeters from the resection
margin. This is most probably the reason that, in approxi-
mately 80% of all cases, recurrent tumor growth occurs
within a 2–3 cm margin of the surgical resection cavity [1].
Inﬁltrative tumor cells are supplied with nutrients and
oxygen by the normal brain vasculature and consequently
protected by the BBB: few anti-cancer drugs are capable of
crossing this barrier to target these cells [2–4]. For a drug
delivery system to be successful at preventing tumor
recurrence, transient, and localized targeting of BBB
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surgical removal of the bulk of the tumor, is necessary.
Attempts to develop pharmaceuticals capable of circum-
venting the BBB, such as lipid-soluble or water-soluble
drugs with high afﬁnities for natural carriers [5–8] have
proven only partially successful. Intra-arterial infusion of
mannitol, which causes dehydration and shrinkage of
endothelialcells,resultsinopeningofthetightjunctionsand
anon-localizedBBBdisruption.Thiswidespreadopeningof
the BBB results in unwanted side effects since potent cyto-
toxic drugs gain access to both the tumor as well as normal
brain in equal quantities. A number of technical difﬁculties
associated with intra-arterial drug delivery, has prevented
the widespread use of this technique [9]. Localized methods
of drug delivery that bypass the BBB altogether, such as
direct intratumoral injection [10, 11] convection-enhanced
delivery [12–14] and controlled release from polymer
implants[15,16]haveonlyshownamodestbeneﬁt.Focused
ultrasoundoffersamethodtodisrupttheBBBnoninvasively
and reversibly at targeted locations [17, 18]; however, this
technique is not well suited to the complex geometry or size
of a post-operative resection cavity.
Clostridium perfringens epsilon toxin (ETX) is of
interest since it is known for its ability to cause widespread
but reversible opening of the BBB [19–21]. ETX is syn-
thesized and secreted as a low toxicity precursor prototoxin
(ETXp) that is converted to fully active toxin by proteolytic
cleavage. Administration of ETXp in a rat model has also
been shown to result in a reduction of the endothelium
barrier antigen in rat brain endothelial cells accompanied
by a reversible opening of the BBB [22].
Photochemical internalization (PCI) is a novel technol-
ogy that can enhance the delivery of macromolecules in a
site-speciﬁc manner [23]. The concept is based on the use
of specially designed photosensitizers, which localize
preferentially in the membranes of endocytic vesicles.
Upon light activation, the photosensitizer interacts with
ambient oxygen causing vesicular membrane damage
resulting in the release of encapsulated macromolecules
into the cell cytosol instead of being transported and
degraded in the lysosomes. PCI has been shown to poten-
tiate the biological activity of a large variety of macro-
molecules and other molecules that do not readily penetrate
the plasma membrane, including proteins (e.g. protein
toxins and immunotoxins), peptides, DNA delivered as a
complex with cationic polymers or incorporated in ade-
novirus or adeno-associated virus, peptide-nucleic acids
and chemotherapeutic agents [24–27].
In a previous study, we have demonstrated that 5-am-
inolevulinic acid (ALA)-mediated PDT was effective in a
temporary opening of the BBB in a limited region of the rat
brain [28]. Although ALA PDT was effective at opening
the BBB, local tissue damage was apparent at ﬂuence
levels just above those required for signiﬁcant BBB deg-
radation thus limiting the usefulness of this method. In
addition, relatively high ﬂuence levels were required for
signiﬁcant BBB disruption.
The purpose of the experiments reported here was to
determine the effects of the chemotherapeutic agent BLM
on small clusters of tumor cells sequestered in otherwise
normal rat brain following localized BBB opening. The
orthotopic brain tumor model used in this study consisted
of F98 glioma cells in Fischer rats. This model exhibits
many of the hallmarks of glioblastoma multiforme (GBM)
and, as such, is considered to be highly relevant in thera-
peutic studies of malignant gliomas [29]. Localized BBB
opening was achieved by PCI-mediated delivery of ETXp
(termed ETXp-PCI), allowing the passage of BLM in the
vicinity of cell implantation. Magnetic resonance imaging
was used to determine the concentration and volume of
gadolinium (Gd) contrast enhancement to infer the extent
of BBB disruption and to track BBB disruption dynamics.
Materials and methods
Experimental animals
Inbred male Fischer rats (Simonsen Laboratories, Inc,
Gilroy, CA) weighing about 350 g were used in this study.
Animal care and protocols were in accordance with insti-
tutional guidelines. Animal holding rooms were maintained
at constant temperature and humidity on a 12 h light and
dark schedule at an air exchange rate of 18 changes per
hour. For the surgical procedures, animals were anaesthe-
tized with Pentobarbital (25 mg kg
-1 i.p.). Buprenorphin
(0.08 mg kg
-1 s.c.) as a post-operative analgesic was
administered to animals following surgery and twice per
day for 3 days thereafter. All animals were euthanized at
the end of the study, or at the ﬁrst signs of distress.
Euthanasia was accomplished with an overdose of Pento-
barbital (100 mg kg
-1 i.p.).
Cell lines
The F98 glioma cell line was originally derived from
transformed fetal CD Fischer rat brain cells following
exposure to ethyl-nitrosourea on the 20th day of gestation
[29]. The F98 cells were grown as monolayers in DMEM
medium (Invitrogen Corp., Carlsbad, CA) with 10% fetal
bovine serum (FBS), 25 mM HEPES buffer (pH 7.4),
penicillin (100 U ml
-1) and streptomycin (100 lgm l
-1)a t
37C and 5% CO2. To generate multicell tumor spheroids,
cells (70% conﬂuence) were harvested with trypsin and re-
suspended in DMEM to a ﬁnal volume of 5 ml. The cell
suspension was transferred to a petri dish coated with a 1:1
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123solution of 2% agar and 29 DMEM and fresh medium
were added to a total volume of 20 ml. The dish was placed
in an incubator and cell clusters were observed within 24 h.
After a week, spheroids were transferred to a non-coated
dish for culturing. Approximately 24 h prior to experi-
mentation, a microscope was used to manually select
spheroids of approximately 450 lm diameter.
Direct BLM or ETXp toxicity assay
Puriﬁed ETXp was obtained from the School of Veterinary
Medicine, University of California, Davis, San Bernardino,
Ca. ETXp was prepared from an overnight culture of
C. perfringens type D (strain NCTC 8346) in tripticase–
yeast–glucose medium, under anaerobic conditions at 37C.
The overnight cultures were centrifuged at 10,000 rpm for
30 min at 4C and the supernatant containing epsilon toxin
was saved for toxin puriﬁcation. The toxin was then pre-
cipitated by ammonium sulphate. Two columns were pre-
pared with DEAE and CM Sepharose (Pharmacia, Sweden),
respectively, equilibrated in 10 mM Tris, pH 7.5. The toxin
was applied to the DEAE column and the efﬂuent was
monitored at 220 nm. The initially eluted peak was saved
and applied to the CM column. Again the efﬂuent was
monitored at 220 nm and the ﬁrst peak was collected, dia-
lyzed against distilled water and freeze-dried. This product
was shown to contain pure epsilon prototoxin when tested
by SDS PAGE. Prior to its use in these experiments, the
prototoxin was reconstituted in Ringer and activated by
incubation at 37C during 30 min with 0.1% trypsin
(Sigma).
F98 cell monolayers were incubated in increasing con-
centrations (0.1–10 lgm l
-1) of BLM-containing medium
(Sigma, St. Louis, MO) or increasing concentrations of
ETXp (1:200–1:25 dilution) for 4 h. Following exposure to
BLM or ETXp, the cell monolayers were washed, har-
vested with trypsin, counted using a Coulter Counter
(Beckman Coulter, Model Z, Fullerton, CA) and then
incubated at various cell densities in complete media for
11–14 days to allow for colony growth. Colonies that grew
from the surviving cells were stained with crystal violet
and counted ([50 cells/colony).
ETXp-PCI toxicity assay
F98 cell monolayers were incubated in serum-containing
medium with 1 lgm l
-1 photosensitizer (aluminum phtha-
locyanine disulfonate; AlPcS2a) for 18 h, washed 3 times
with medium and incubated inBLM (0.25 lgm l
-1)o rCl. p
(dilution 1:50) containing medium for 4 h. Following
incubation, monolayers were washed once with medium,
resuspended in drug-free medium, and irradiated with
670 nm light from a diode laser (Intense Ltd, North
Brunswick, NJ). The cells were exposed to a radiant
exposure of 1.5 J cm
-2 delivered at a light irradiance of
5m Wc m
-2. PDT-only controls received AlPcS2a and light
as described above but no drug was administered. BLM or
ETXp controls received no photosensitizer or light. Fol-
lowing irradiation, cells were harvested and prepared for
colony growth as described in the previous section. A total
of three experiments were performed.
Migration assay
The cell migration assay has been described previously
[30]. Brieﬂy, the matrix used in these experiments con-
sisted of a collagen gel composed of 70% type I rat tail
collagen at a concentration of 4 mg ml
-1, 20% 59 DMEM
and 10% reconstituted buffer made of 260 mM sodium
bicarbonate and 200 mM HEPES. Single F98 tumor
spheroids (450 lm diameter) were placed in imaging
dishes coated with a thin layer of dried rat tail type I col-
lagen. After an hour to allow for spheroid adhesion, 200 ll
of the collagen gel matrix was deposited over the spheroid
and allowed to gel. The cultures were then overlaid with
400 ll of culture medium containing 10% FBS and BLM
(0.1–1 lgm l
-1 Sigma, St. Louis, MO) for 4 h, washed
once with medium and resuspended in drug-free medium.
Within a few hours of spheroid placement in the collagen
type I gel, individual cells began to detach from the surface
of the spheroid and migrate into the surrounding matrix.
Eighteen hours following implantation, the cells had
migrated to an average distance of 2–300 lm. Invasion
distance was calculated daily as the distance in microme-
ters from the spheroid edge to the population of cells most
distant from the spheroid edge.
ETXp-PCI induced BBB degradation
in non-tumor-bearing rats
Non-tumor-bearing animals were divided into three groups:
(1) PDT controls, (2) ETXp controls, or (3) PCI
(PDT ? ETXp). Animals in the ETXp-only group were
administered 0.7 ml (i.p.) of 1:10, 1:50 or 1:100 dilutions
of ETXp stock solution (1 mg ml
-1). The toxicity and
extent of BBB disruption induced by different concentra-
tions ETXp were evaluated from animal survival and MR
images.
Animals in the PCI treatment group were injected with
AlPcS2a (1 mg kg
-1 i.p.) and 48 h later, a 1:100 dilution
of ETXp was administered i.p. At the time of light
treatment, anaesthetized rats were ﬁxed in a stereotactic
frame (David Kopf Instruments, Tujunga, CA), a skin
incision was made exposing the skull and an optical ﬁber
coupled to a 670 nm diode laser was placed in contact
with the surface of the skull 1 mm posterior to the
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123bregma and 2 mm to the right of the midline. Surface
light irradiation was given approximately 60 min after
ETXp administration at light ﬂuences of 0.5, 1.0 and 2.5 J
at a ﬂuence rate of 10 mW. Following treatment, the
wound was closed with sutures and the rats removed from
the frame. PDT controls consisted of photosensitizer and
light treatment as described above but in the absence of
ETXp administration.
BLM treatment of tumor cell injected animals
The protocol for these experiments was as follows. Newly
implanted glioma cells were used as a proxy for inﬁltrating
cells remaining in the resection margin following surgical
removal of bulk tumor. BBB opening was initiated 24 h
following cell inoculation—a time considered to be insuf-
ﬁcient to allow for the development of bulk tumor and
BBB degradation, but long enough for the cells to form
small sequestered micro-clusters protected by an intact
BBB. To establish intracranial tumors, anaesthetized rats
were ﬁxed in the stereotactic frame as previously descri-
bed. The skin was incised and a 1.0-mm burr hole was
made at the following coordinates: 1 mm posterior to the
bregma, 2 mm to the right of the midline and at a depth of
2 mm. The injection device consisted of a 30-G blunt
cannula connected through a catheter (Hamilton Co., Reno,
NV) to an infusion pump (Harvard Apparatus, Holliston,
MA). The cannula was ﬁxed in the electrode holder of the
stereotactic frame, and then vertically introduced into the
brain. A total of 10,000 cells in 5 ll PBS were injected into
the brain during a period of 2 min. Following injection, the
cannula was kept in place for 2 min, and slowly retracted
to prevent the spread of tumor cells. Closure was done with
bone wax and sutures. Twenty-four hours later, ETXp was
administered intraperitoneal at a concentration described
previously. At the time of light treatment, anaesthetized
rats were ﬁxed in the stereotactic frame the skin incision
was reopened exposing the skull and an optical ﬁber was
placed in contact with the surface of the skull at the point
of cell implantation. Surface light irradiation was given
approximately 60 min after ETXp administration at a light
ﬂuence levels of 1.0 J at a ﬂuence rate of 10 mW. Fol-
lowing treatment the wound was closed with sutures and
the rats freed from the frame. Bleomycin (4 mg/kg) was
injected i.p. at the time of light treatment and repeated ﬁve
additional times at 12 h intervals. Control animals received
no treatment or PDT and BLM in the absence of ETXp.
MR imaging
Isoﬂurane-anesthetized animals were imaged on days 1, 3,
5, 8 and 18 post-PCI treatment in a 7.0 T animal MR
scanner (Bruker Corp., Billerica, MA). A small surface
coil was placed on top of the target area and 0.8 ml of a
Gd-based contrast agent (Multihance: Bracco Diagnostics,
Inc, Princeton, NJ), was injected i.p. T1-weighted (TR =
700 ms; TE = 14 ms) post-contrast MR image were
taken 15–20 min after contrast injection. Since Multi-
hance, with a molecular weight of 1058.2, is too large to
cross the intact BBB, any contrast enhancement evident
on T1-weighted images was taken as direct evidence of
BBB disruption induced by the corresponding treatment.
To evaluate the extent of edema reaction, T2-weighted
images (TR = 4,200 ms; TE = 36 ms) were also
acquired for each animal. Gd concentration was estimated
as follows. Four calibration tubes with known Gd con-
centrations in gray-matter-mimicking saline were scanned
and the intensities analyzed using MIPAV (Medical
Image Processing, Analysis & Visualization) software. It
was assumed that the relationship between the Gd con-
centration and the signal intensities in white and gray
matter were similar to that of the calibration tubes and
therefore, the calibration curve derived from these mea-
surements could be extrapolated to brain tissue as previ-
ously described [28].
Data analysis
The extent of BBB disruption for each treatment was
evaluated from the degree of contrast enhancement
observed on T1 post-contrast images. The qualitative
analyses of contrast and edema volumes were performed
using MIPAV software. Both contrast and edema volumes
were ﬁrst manually contoured on each T1 slice. The total
volume was then calculated automatically by the software
according to the following equation: V ¼
P
i ðSi   TÞ cm3
where Si represents the contrast area contoured on each
slice and T represents the image slice thickness. A thick-
ness of 1.0 mm was used in all MR images acquired in this
study.
Histological preparation
Animals were sacriﬁced 21 days following ETXp-PCI
BBB opening and their brains extracted. The brains were
sectioned at the point of light application and ﬁxed by
immersion in 10% buffered (pH 7.2) formalin prior to
parafﬁn embedding. Four micrometer thick coronal sec-
tions were obtained from the original cut surface repre-
senting the position of the light applicator. The sections
were routinely processed for the production of hematoxylin
and eosin (H&E) sections and examined under a light
microscope by an independent pathologist blinded to the
treatment modes.
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In vitro studies
The direct cytotoxic effects of either BLM or ETXp on F98
monolayers are shown in Fig. 1a and b. The cells were
exposed to either agent for 4 h and then assayed with
respect to their ability to form new cell colonies after 11–
14 days in culture. Increasing concentrations of BLM
caused a decreasing survival of colony forming cells and at
a concentration of 5 lgm l
-1 less than 5% of the cells
survived (Fig. 1a). In contrast, ETXp did not appear to be
toxic to the monolayers, even at the highest concentration
tested (Fig. 1b).
In order to determine the effects of ETXp-PCI in vitro,
experiments were performed on F98 cell monolayers. The
monolayers were incubated with the photosensitizer for
18 h, followed by 4 h incubation with ETXp (dilution
1:50) and thereafter irradiated with 670 nm light
(1.5 J cm
-2). PDT-only controls received AlPcS2a and
light but no ETXp. ETXp controls received neither pho-
tosensitizer nor light. As can be seen in Fig. 2a, there was
no signiﬁcant increase in the toxic effects of PCI-mediated
delivery of ETXp compared to the PDT controls. In con-
trast, BLM-PCI produced signiﬁcant cell toxicity compared
to both PDT and BLM control cultures (Fig. 2b). Only 24%
of the ETXp-PCI BLM treated cultures survived treatment
compared to 78% and 74% for the PDT and BLM control
cultures respectively. The BLM-PCI effect was signiﬁ-
cantly higher than the additive effects of PDT and BLM on
these cells.
Both tumor cell proliferation and migration are impor-
tant for tumor progression in the brain. The ability of BLM
to inhibit F98 cell migration into a collagen matrix in vitro
is shown in Fig. 3. High concentrations of BLM that
clearly inhibited the ability of cells to form colonies had
minimal effect on cell mobility (Fig. 3). Even at a BLM
concentration of 1 lgm l
-1, which produced a 65% inhi-
bition of F98 cell proliferation, only a slight decrease in
cell migration was observed.
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Fig. 1 Cytotoxic effects of BLM or ETXp on F98 monolayers. F98
cell monolayers were incubated in increasing concentrations. a (0.1–
10 lgm l
-1) of bleomycin-containing medium or increasing concen-
trations of (b): ETXp (1:200–1:25 dilution). BLM had a signiﬁcant
inhibitory effect on the ability of the cells to form colonies while
ETXp had little effect. Data points represent the mean of 3
experiments ± standard error
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Fig. 2 Effects of ETXp-PCI or BLM-PCI on F98 monolayers.
a ETXp-PCI had no signiﬁcant toxic effect on F98 cells in contrast to
(b): the effect of BLM-PCI. Control groups consisted of; no
treatment, ETXp, or BLM no light, and PDT only. Data points
represent the mean of 3 experiments ± standard error
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The toxicity of ETXp delivered either by intra peritoneal
(i.p.) or intracranial (i.c.) injection was evaluated in a
number of animals. Animals surviving for more than
20 days were considered to have survived. As shown in
Fig. 4, all animals receiving ETXp i.c. survived. In con-
trast, the delivery of ETXp to animals via i.p. injection
proved to be much more toxic resulting in death of all
animals receiving a dose of 1:10. It is interesting to note
that, although i.p. administration resulted in signiﬁcant
mortality, no evidence of localized contrast (BBB disrup-
tion) was observed on MR images in animals that survived
(data not shown). Overall, the results suggest that i.c.
injection or i.p. injection of ETXp at a dilution of 1:100 or
higher were well tolerated and therefore provided the
rationale for its use in the BBB experiments.
PDT and PCI-induced BBB disruption
Localized regions of increased signal intensity on T1-
weighted MRI scans were used as a marker for BBB dis-
ruption in the rat brain. Both the volume of the enhancing
region and the signal intensity were measured at speciﬁc
time intervals following i.p. contrast injection. Forty-eight
hours following AlPcS2a injection (1 mg kg
-1 i.p.) light
treatment was given to three groups of rats (n = 4 per
group) to a ﬂuence level of 0.5, 1.0 or 2.5 J using a ﬂuence
rate of 10 mW. Typical post-contrast MRI scans performed
3 days after PDT (photosensitizer ? light) or PCI (ETXp,
photosensitizer ? light), are illustrated in Fig. 5. The scans
were taken 15 min following i.p. contrast injection. Clear
evidence of signiﬁcantly increased local BBB disruption is
seen following light treatment in the presence of ETXp
compared to PDT treatment for the two lowest ﬂuence
levels. This is evidenced by the localized contrast
enhancement observed directly below the position on the
skull where the light delivery ﬁber tip was positioned.
Average contrast volumes and intensities for the four ani-
mals in each group are shown in Fig. 6a and b respectively.
The degree of contrast enhancement (and hence BBB dis-
ruption) is clearly ﬂuence dependent for both PDT and PCI.
Zero to minimal enhancement was observed for PDT at the
two lowest ﬂuences (0.5 and 1 J) investigated. In contrast,
signiﬁcant enhancement was seen in the ETXp-PCI ani-
mals. At a ﬂuence of 2.5 J, the PDT effect was so pro-
nounced that the addition of ETXp had no apparent effect
on BBB disruption. The concentration of the contrast
medium in the brain (calculated from the calibration curve
derived from the Gd standard tubes shown in Fig. 7a and b)
is shown in Fig. 8. Contrast concentrations of 0.2 and
1.4 mg ml
-1 for PDT and PCI treatment respectively were
obtained for a 1 J ﬂuence level. In the absence of photo-
sensitizer (light-only control), high ﬂuences (2.5 J) dem-
onstrated no apparent increased signal in the region of light
treatment compared to normal brain.
Histological analysis
Coronal H&E sections (a and c) obtained from rat brains
21 days post treatment and corresponding T1 MRI scans
acquired3 dayspost-treatment(bandd)areshowninFig. 9.
In tissue volumes subjected to ETXp-PCI and light no
signiﬁcant histological changes were observed in coronal
sections obtained from animals exposed to ﬂuences of 0.5 J
(data not shown) or 1 J (Fig. 9a). At ﬂuence levels above
2.5 J, even in the absence of ETXp a focally extensive area
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Fig. 3 Effects of BLM on F98 cell migration from multicell
spheroids. Single F98 tumor spheroids were implanted in a collagen
matrix overlaid with culture medium containing bleomycin (0.1–
1 lgm l
-1). Invasive distance was calculated after 4 days in culture
as the distance in lm from the spheroid edge to the most distant
population of invasive cells. BLM had little effect on cell migration.
Each data point represents the mean (±standard error) of three
experiments
Fig. 4 Surviving fraction of animals subjected to ETXp. Two
administration routes were compared: direct intracranial injection
(i.c.; 5 ll total volume), and intraperitoneal injection (i.p.; 0.7 ml
total volume). The n value above each data bar indicates the total
number of animals used per group
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123of necrosis and degeneration of brain parenchyma and
inﬁltration of lymphocytes, plasma cells and foamy mac-
rophages (Gitter cells), was apparent in the area directly
below the application of light (Fig. 9c). Some of the Gitter
cells contained hemosiderin which is suggestive of hem-
orrhage. Blood vessels in these sections showed hypertro-
phic and hyperplastic endothelium.
Time course of BBB disruption
Of particular interest is the time duration and evolution of
the ETXp-PCI BBB disruption since this represents the
therapeutic window for drug delivery. Typical post-con-
trast MRI scans performed 1, 3, 5, and 18 days after ETXp-
PCI treatment are illustrated in Fig. 10a–d respectively.
ETXp was given i.p. at a dilution of 1:100 and a light
ﬂuence of 1 J was employed. The scans were taken 15 min
following i.p. contrast injection. Enhancement volumes
peaked on day 3 suggesting maximum BBB disruption at
that time. Thereafter, contrast volumes were observed to
decrease and by day 11, only trace amounts of contrast
were observed in the 0.5 and 1 J animals. Animals treated
with 2.5 J demonstrated signiﬁcant contrast volumes even
at 14 days post-treatment. Figure 11 shows the average
BBB opening time as inferred from enhancing volumes for
four ETXp-PCI and four PDT control animals. The opti-
mum therapeutic drug delivery window appeared to be
between days 2 and 5 following BBB opening.
In order to study the dynamics of ﬂow into the region of
the brain where the BBB was opened by ETXp-PCI, 4
Fig. 5 T1-weighted MRI
contrast enhanced images
showing focal contrast
enhancement directly below the
light source. Forty-eight hours
following AlPcS2a injection
(1 mg kg
-1 i.p.) light treatment
was given to three groups of rats
(n = 4 per group) to a ﬂuence
level of 0.5, 1.0 or 2.5 J using a
ﬂuence rate of 10 mW. The
scans were performed 3 days
after PDT
(photosensitizer ? light) or PCI
(ETXp,
photosensitizer ? light). The
scans were taken 15 min
following i.p. contrast injection
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Fig. 6 a Average contrast volume and b signal intensity measured
from MRI scans performed 3 days post PDT or ETXp-PCI treatment
for three light ﬂuences (0.5, 1, 2.5 J; ﬂuence rate = 10 mW). Each
data point represents the mean (±standard error) of four animals
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123animals were scanned 5 and 60 min following i.p. contrast
injection. Disruption of the BBB results in ﬂow of blood
plasma components into the surrounding brain tissue
causing edema formation. This is clearly evident in the
T2—weighted scan shown in Fig. 12a. The region of
edema was localized to the illuminated portion of the brain
in all of the treated animals. As can be seen from the T1
MRI scan taken 5 min post i.p. contrast injection (Fig. 12b)
enhancement appears mainly around the periphery of the
edema region. The animal was rescanned 60 min after
contrast injection and now the contrast was evenly dis-
tributed throughout the volume of illuminated brain tissue
(Fig. 12c).
Effects of BLM on tumor formation
Fifteen animals were divided into three groups: non-treated
controls (group 1), PDT-BLM controls (group 2) and
ETXp-PCI-BLM (group 3). Animals in groups 2 and 3
were injected with AlPcS2a (1 mg kg
-1, i.p.) and 24 h later
1 9 10
4 cells were implanted. After an additional 24 h,
animals in group 3 were given ETXp i.p. and 1 J of light
was delivered to both groups 2 and 3. BLM (4 mg kg
-1)
was injected i.p. at the time of light treatment and there-
after, every 12 h over 3 days for a total of six doses
(24 mg kg
-1). Animals were euthanized at the ﬁrst signs of
distress due to increased intracranial pressure, neurological
deterioration or weight loss of more than 10%. Kaplan–
Meier survival curves are shown in Fig. 13. Tumor cell
injection was lethal in 100% of controls with no survivors
past day 33. The animals in the BLM-PDT group all suc-
cumbed but their survival was signiﬁcantly increased
compared to controls (P\0.01). In contrast, 60% of the
animals in the ETXp PCI-BLM group survived more than
70 days and one animal was considered a long-term
survivor.
Discussion
The inherent tendency of glial tumors to inﬁltrate normal
brain tissue signiﬁcantly limits the effectiveness of con-
ventional treatments. Although surgical resection reduces
the pressure effects of the bulk tumor, it is the diffusely
invading tumor cells beyond the resection margin that are
responsible for the damage to normal brain parenchyma
which ultimately results in the death of the patient. In this
study, we have employed the anti-neoplastic agent bleo-
mycin, a glycopeptide antibiotic which acts by induction of
DNA strand breaks, applied through a targeted opening of
the BBB to inhibit tumor formation in the rat brain. Newly
implanted tumor cells were used to mimic the character-
istics of inﬁltrating cells remaining in the resection margin
usually found following surgical removal of bulk tumor.
Localized BBB opening was performed 24 h after cell
inoculation. This is an insufﬁcient time to allow for the
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Fig. 7 a T1-weighted MR images of a ETXp-PCI treated rat along
with four calibration tubes with Gd concentrations of 0 (a), 0.5 (b), 1
(c) and 2 (d) mg/ml. b MRI signal intensity as a function of Gd
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Fig. 8 Average contrast concentrations as a function of ﬂuence level.
The concentrations were derived from MRI scans performed 3 days
post PDT or ETXp-PCI treatment for three light ﬂuences (0.5, 1,
2.5 J; ﬂuence rate = 10 mW). Each data point represents the mean
(±standard error) of four animals
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123Fig. 9 Effects of ﬂuence level
on tissue disruption. Coronal
H&E sections (a, c) from rat
brains corresponding to T1
contrast MRI scans (b) and (d).
The sections were taken 21 days
post-treatment and the T1-
weighted post-contrast images
were acquired 3 days post-
treatment. In the area exposed to
the highest ﬂuence level (close
to the dura) no signiﬁcant
pathology (a) was observed
following delivery of 1 J. At a
ﬂuence level of 2.5 J, extensive
inﬁltration of lymphocytes and
macrophages, some loaded with
hemosiderin, was apparent
Fig. 10 T1-weighted MRI
contrast enhanced images
showing focal contrast
enhancement at: a—1, b—3,
c—5 and d—18 days post-
treatment. ETXp-PCI treatments
using 1 J were performed at a
ﬂuence rate of 10 mW. All
animals were scanned 15 min
following i.p. contrast injection.
A localized contrast
enhancement is clearly seen 1–
5 days following light treatment
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123development of bulk tumor and BBB degradation, but long
enough for the cells (doubling time of approximately 18 h)
to form small sequestered micro-clusters which are pro-
tected by an intact BBB.
The data presented in Fig. 1 show that while BLM had a
pronounced effect on the proliferation of F98 cells in vitro,
ETXp did not. This is in agreement with studies suggesting
that ETX-induced effects occur speciﬁcally in cells
expressing the tight junction proteins claudin-3 and/or
claudin-4, which function as low- and high-afﬁnity recep-
tors for ETX, respectively [31, 32]. Other recent studies
show little or no claudin-3 or claudin-4 mRNA expression
in whole-brain tissue, consistent with the fact that these
proteins are expressed usually in cells of epithelial origin
such as endothelial cells, whereas glia cells and neurons are
of mesenchymal origin [33]. The data illustrated in Fig. 2a
show that there is no signiﬁcant difference in survival of
cells exposed to ETXp-PCI and PDT, suggesting that the
observed cytotoxicity in both groups was due entirely to
the PDT effect. ETXp proved however to be highly toxic in
animals when given i.p. in high concentrations (Fig. 4). A
plausible explanation for the observed toxicity is protease-
induced prototoxin activation in the body. This could occur
following internalization in rat peritoneal macrophages and
subsequent conversion to toxin via lysosomal degradation.
Absorption of the activated toxin via the peritoneum
may have produced the toxic effects observed following
administration of high concentrations ETXp. Since glia
derived F98 cells most probably lack the receptors (clau-
dins) for the prototoxin, it will not be internalized and
therefore not converted to the active toxin in these cells. In
contrast, brain capillary endothelial cells are rich in both
claudin-3 and -4 since these cells form tight junctions, and
therefore can convert the prototoxin into the active toxin.
Binding of the epsilon toxin to the brain capillary endo-
thelium results in a reversible loss of BBB integrity and
hence increased vascular permeability. For example, in
studies using horse-radish peroxidase as a tracer, it has
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Fig. 11 Average time course of BBB opening induced by PDT or
ETXp-PCI. The animals (n = 4 per group) received 1 mg kg
-1
AlPcS2a. and a light ﬂuence of 1 J. The PCI group of animals also
received an i.p. injection of ETXp at a concentration of 1:100. Both
PDT and PCI animals were scanned on days 1, 3, 5, 8 and 18 after
treatment. All T1 post-contrast images were taken 15 min following
i.p. contrast injection
Fig. 12 Dynamics of local contrast ﬂow. a T2-weighted scan showing edema localized to the illuminated portion of the brain. b T1 MRI scans
taken 5 min and c 60 min post i.p. contrast injection
Fig. 13 Kaplan–Meier survival of tumor cell implanted animals. All
animals received 1 9 10
4 cells i.c. Three groups were followed: non-
treatedcontrols,PDT-BLMcontrols(AlPcS2a ? 1 J),ETXp-PCIBLM
experimental group(AlPcS2a ? ETXp ? 1 J);BLM(4 mg kg
-1)was
injected i.p. twice daily for 3 days
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123been shown that this enzyme leaks from murine brain
blood vessels within 1 h of intravenous toxin administra-
tion [34].
It is hypothesized that the biological effects of the ETXp
on the BBB is potentiated by PCI, but only in areas of the
brain exposed to adequate light ﬂuences. Due to this
potentiation effect, sub-threshold ETXp doses will be suf-
ﬁcient to open the BBB, but this low ETXp dose will be
inadequate to open the BBB in regions where the light
ﬂuence is insufﬁcient to evoke the PCI effect. The validity
of this hypothesis is supported by the results presented in
Figs. 5 and 6 which show that increasing light ﬂuences
(0.5–2.5 J) resulted in increasing BBB disruption. In a
related study, we have shown that ALA-mediated PDT at
relatively high ﬂuences (9–26 J) could also produce BBB
degradation [28]. In this case, the BBB opened after 2 h but
was essentially closed 72 h later. In contrast, the time
course for ETXp-PCI BBB opening was much longer
(Figs. 10 and 11) peaking at day three or four and closing
by day 14. This is clinically relevant as it would provide an
effective long interval for drug delivery. As evidenced
from histological sections (Fig. 9a), the effects of ETXp-
PCI were reversible only if the ﬂuence level was kept at or
below 1 J since no permanent damage was observed at
these ﬂuence levels. In contrast, higher ﬂuence levels,
where the direct PDT effect on endothelial cells predomi-
nated, resulted in signiﬁcant localized tissue damage
(Fig. 9c). Based on histological evaluation, the tissue
damage and immune cell inﬁltration observed in regions
close to the light source were consistent with cerebral
ischemia resulting in a localized stroke. This is consistent
with the intense contrast enhancement observed on MR
images: contrast enhancement is considered to be one of
the signatures of BBB breakdown in cerebral ischemia.
Although a detailed understanding of the reversible low
light ﬂuence BBB disruption seen in these experiments is at
present unknown, a direct effect on the capillary endothe-
lial cells is the most probable cause. This would include
direct interaction of ETX on the endothelial cell cyto-
skeleton in the illuminated regions that could lead to cell
rounding and contraction, with the formation and/or
enlargement of endothelial gaps that have previously been
described in response to PDT [35]. Additionally, low ﬂu-
ence rate/low ﬂuence PDT has been demonstrated to
enhance the delivery of macromolecular drug carriers, in
particular liposomally encapsulated doxorubicin, into
murine colon carcinoma tumors growing in the shoulders
of mice [36].
In this study, newly implanted F98 cells were used to
mimic the characteristics of inﬁltrating cells. F98 glioma
growth in vitro and in vivo morphology have been described
in detail, and the tumor has been classiﬁed as an anaplastic
or undifferentiated glioma with many characteristics that
closely resemble those of human GBM and anaplastic
astrocytoma. As few as 100 tumor cells injected into the
brains of Fischer rats have been shown to be lethal [29].
This tumor has also been shown to be refractory to several
forms of chemotherapy and radiotherapy in vivo and, as
such, is considered a good model for evaluating experi-
mental therapies where survival is the endpoint [37]. In the
survival experiments shown in Fig. 13, 10,000 cells were
inoculated. Therefore, a cell kill of 99% would be required
in order to completely prevent tumor formation. Only one
animal seemed to be ‘‘cured’’ but the survival time in the
ETXp-PCI group was signiﬁcantly increased compared to
non-treated controls or controls that received PDT-BLM.
Since BLM did not appear to inhibit F98 cell migration
(Fig. 3) it is conceivable that some cells were able to
migrate into an area of the brain where the BBB was still
intact: i.e. out of the region where the ﬂuence level was
sufﬁcient to open the BBB. These cells could potentially
give rise to delayed tumor formation since migratory cells
have a lower proliferation rate and are more resistant to
apoptosis [38]. The in vitro data shown in Fig. 1a suggest,
that a BLM concentration in excess of 5 lgm l
-1 would be
required to eliminate more than 90% of the F98 cells. In the
MR imaging studies, average contrast concentrations in the
treatment volumes (1 J light ﬂuence) were 1.4 and
0.2 mg ml
-1 in ETXp-PCI and PDT groups, respectively
(Fig. 8). Since 375 mg of Gd contrast was given i.p. to each
animal prior to scanning, the concentration in the region of
BBB opening would represent less than 0.5% of the injected
dose. If this ratio of total dose to brain concentration is
similar for BLM, this suggests a drug concentration of
approximately 7.5 lgm l
-1 was obtained in the vicinity of
the implanted cells following i.p. administration of 1.5 mg
BLM. According to the in vitro results, this concentration is
likely inadequate for the elimination of 99% of the
implanted cells. Based on these calculations, it is not sur-
prising that most of the animals developed tumors. Even so,
the treatment resulted in extended survival compared to
controls. It should be pointed out that since BLM has a
higher molecular weight than Gd contrast, the actual con-
centration of the drug in the vicinity of the implanted cells
was likely overestimated. Since increased survival was the
endpoint for BLM efﬁcacy, no attempt was made to mea-
sure the actual BLM concentration in the brain.
Increased localized tissue pressure due to edema for-
mation following localized BBB disruption is a potential
problem in a compressed brain, such as the rat model used
in this study. As shown in Fig. 12, the increased intracra-
nial pressure due to tumor compression caused a signiﬁcant
reduction in contrast ﬂow rate. From a clinical point of
view, this effect can be managed effectively post-opera-
tively in patients that have undergone decompressive cy-
toreductive surgery. In this case, light could be applied via
J Neurooncol (2009) 95:317–329 327
123an indwelling balloon applicator implanted in the resection
cavity and the BBB disruption would be limited to the
walls of the cavity [39].
ETX has recently been shown to cause rapid destruction
of certain types of cancer cells expressing the ETX
receptors claudin-3 and claudin-4. Unfortunately, the util-
ity of this toxin is limited by systemic toxicity because its
receptors are expressed in numerous organs as evidenced
from the data presented in Fig. 4. The results of the present
study suggest however that, under the appropriate condi-
tions, PCI is a safe and efﬁcient method for the selective
disruption of the BBB in rats. Due to ETX or ETXp tox-
icity, it is highly unlikely that ETXp-based PCI approaches
will be used in human clinical protocols. Nevertheless, the
results presented herein provide the basis for further PCI
studies using non-toxic vasoactive compounds including
bradykinin and its analogs, leukotrienes and histamine
[40–42].
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